Advanced search
Publication Cover
Cancer Investigation Volume 28, 2010 - Issue 8
Submit an article Journal homepage
300
Views
14
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLEClinical Translational Therapeutics

Implications of Mutational Analysis for the Management of Patients With Gastrointestinal Stromal Tumors and the Application of Targeted Therapies

Agnieszka WozniakDepartment of General Medical Oncology and Laboratory of Experimental Oncology, Centre for Human Genetics, Department of Pathology, University Hospitals Leuven, Leuven Cancer Institute, Catholic University Leuven, Leuven, BelgiumCorrespondence[email protected]
,
Giuseppe FlorisDepartment of General Medical Oncology and Laboratory of Experimental Oncology, Centre for Human Genetics, Department of Pathology, University Hospitals Leuven, Leuven Cancer Institute, Catholic University Leuven, Leuven, Belgium
,
Maria Debiec-RychterDepartment of General Medical Oncology and Laboratory of Experimental Oncology, Centre for Human Genetics, Department of Pathology, University Hospitals Leuven, Leuven Cancer Institute, Catholic University Leuven, Leuven, Belgium
,
Raf SciotDepartment of General Medical Oncology and Laboratory of Experimental Oncology, Centre for Human Genetics, Department of Pathology, University Hospitals Leuven, Leuven Cancer Institute, Catholic University Leuven, Leuven, Belgium
&
Patrick SchöffskiDepartment of General Medical Oncology and Laboratory of Experimental Oncology, Centre for Human Genetics, Department of Pathology, University Hospitals Leuven, Leuven Cancer Institute, Catholic University Leuven, Leuven, Belgium
Pages 839-848 | Published online: 06 Aug 2010

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Bochao Zhao, Jingting Zhang, Di Mei, Jiale Zhang, Rui Luo, Huimian Xu & Baojun Huang. (2018) The assessment of different risk classification systems for gastrointestinal stromal tumors (GISTs): the analytic results from the SEER database. Scandinavian Journal of Gastroenterology 53:10-11, pages 1319-1327.
Read now

Articles from other publishers (13)

Szymon Macioszek, Danuta Dudzik, Margot Biesemans, Agnieszka Wozniak, Patrick Schöffski & Michal J. Markuszewski. (2023) A multiplatform metabolomics approach for comprehensive analysis of GIST xenografts with various KIT mutations . The Analyst 148:16, pages 3883-3891.
Crossref
Gulgun Engin, Serpil Eraslan, Hülya Kayserili, Yersu Kapran, Haluk Akman, Ali Akyuz & Nuri Faruk Aykan. (2017) Imatinib response of gastrointestinal stromal tumor patients with germline mutation on KIT exon 13: A family report. World Journal of Radiology 9:9, pages 365-370.
Crossref
Divya Gupta, Laxmisha Chandrashekar, Lidia Larizza, Elisa A. Colombo, Laura Fontana, Cristina Gervasini, Devinder M. Thappa, Medha Rajappa, Kalai Selvi Rajendiran, Gubbi Shamanna Sreenath & Vikram Kate. (2017) Familial gastrointestinal stromal tumors, lentigines, and café-au-lait macules associated with germline c-kit mutation treated with imatinib . International Journal of Dermatology 56:2, pages 195-201.
Crossref
Kazuyoshi Yamamoto, Toshimasa Tsujinaka, Tsuyoshi Takahashi, Shinsuke Sato, Yukio Nishiguchi, Yasuo Nakashima, Kazuya Muguruma, Seiichi Hirota & Toshiro Nishida. (2014) Impact of the Japanese Gastric Cancer Screening System on Treatment Outcomes in Gastric Gastrointestinal Stromal Tumor (GIST): An Analysis Based on the GIST Registry. Annals of Surgical Oncology 22:1, pages 232-239.
Crossref
Brian K. Bednarski, Dejka M. Araujo, Min Yi, Keila E. Torres, Alexander Lazar, Jonathan C. Trent, Janice N. Cormier, Peter W. T. Pisters, Dina Chelouche Lev, Raphael E. Pollock, Barry W. Feig & Kelly K. Hunt. (2014) Analysis of Prognostic Factors Impacting Oncologic Outcomes After Neoadjuvant Tyrosine Kinase Inhibitor Therapy for Gastrointestinal Stromal Tumors. Annals of Surgical Oncology 21:8, pages 2499-2505.
Crossref
Gan WeidongQu Feng, Sun Xitai, Yan Xiang, Guo Hongqian & Jia Ruipeng. (2013) Sunitinib as first-line neoadjuvant therapy in two patients with rectal stromal tumors. Future Oncology 9:11, pages 1697-1701.
Crossref
Richard A. Speight, Annette Nicolle, Stephanie J. Needham, Mark W. Verrill, Jane Bryon & Simon Panter. (2013) Rare, Germline Mutation of KIT With Imatinib-Resistant Multiple GI Stromal Tumors and Mastocytosis . Journal of Clinical Oncology 31:16, pages e245-e247.
Crossref
Michael A Postow & Mark E Robson. (2012) Inherited gastrointestinal stromal tumor syndromes: mutations, clinical features, and therapeutic implications. Clinical Sarcoma Research 2:1.
Crossref
Annika Lehmann, Christiane Schewe, Guido Hennig, Carsten Denkert, Wilko Weichert, Jan Budczies & Manfred Dietel. (2012) Applicability of a System for Fully Automated Nucleic Acid Extraction From Formalin-fixed Paraffin-embedded Sections for Routine KRAS Mutation Testing. Diagnostic Molecular Pathology 21:2, pages 114-119.
Crossref
Patrick A. Plé, Frédéric Jung, Sue Ashton, Laurent Hennequin, Romuald Laine, Christine Lambert-van der Brempt, Rémy Morgentin, Georges Pasquet & Sian Taylor. (2012) Discovery of new quinoline ether inhibitors with high affinity and selectivity for PDGFR tyrosine kinases. Bioorganic & Medicinal Chemistry Letters 22:9, pages 3050-3055.
Crossref
A. Wozniak, P. Rutkowski, A. Piskorz, M. Ciwoniuk, C. Osuch, E. Bylina, J. Sygut, M. Chosia, J. Rys, K. Urbanczyk, W. Kruszewski, P. Sowa, J. Siedlecki, M. Debiec-Rychter & J. Limon. (2012) Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience. Annals of Oncology 23:2, pages 353-360.
Crossref
Piotr Rutkowski, Agnieszka Wozniak, Maria Dębiec‐Rychter, Michał Kąkol, Wirginiusz Dziewirski, Marcin Zdzienicki, Konrad Ptaszynski, Monika Jurkowska, Janusz Limon & Janusz A. Siedlecki. (2011) Clinical utility of the new American Joint Committee on Cancer staging system for gastrointestinal stromal tumors. Cancer 117:21, pages 4916-4924.
Crossref
Jean-Jacques KiladjianRuben A. Mesa & Ronald Hoffman. (2011) The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood 117:18, pages 4706-4715.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.